Literature DB >> 30250349

Technique of Complete Heart Isolation with Continuous Cardiac Perfusion During Cardiopulmonary Bypass: New Opportunities for Gene Therapy.

Michael G Katz1, Anthony S Fargnoli1, Charles Yarnall2, Angel Perez3, Alice Isidro4, Roger J Hajjar1, Charles R Bridges1.   

Abstract

Cardiopulmonary bypass (CPB) featuring complete heart isolation and continuous cardiac perfusion is a very promising approach for solving the problem of efficient gene delivery. In the technique presented here, separate pumps are used for the systemic and cardiac circuits. This system permits continuous isolated arrested heart perfusion through optimizing a number of delivery parameters including temperature, flow rate, driving pressure, ionic composition, and exposure time to the cardiac vessels. During complete cardiac isolation, the blood vector concentration trended from 11.51 ± 1.73 log genome copies (GCs)/cm3 to 9.84 ± 1.65 log GC/cm3 (p > .05). Despite restructuring a very high concentration to the heart, GCs were detectable in the systemic circuit. These values over time were near negligible by comparison but detectable 1.66 ± .26 during 20 minutes of recirculation and did not change (p > .05). After the completion of the recirculation interval and subsequent washing procedure, the initial systemic blood vector GC concentration slightly increased to 2.08 ± .38 log GCs/cm3 (p > .05). During the recirculation period, we supported flow via the cardiac circuit around 300 mL/min. In this technique of heart isolation with continuous cardiac perfusion, >99% of the vector remains in coronary circulation during recirculation period. The animal's non recirculation blood, or that in the system, was routinely tested during and after recirculation to contain much less than 1% of the original dose obtained via logging concentration of therapeutic over time. All of the sheep in this group recovered from anesthesia and received critical postoperative care, including all organ function, in the first 24-36 hours. Twenty-one sheep (84%) survived to euthanasia at 12 weeks. Average CPB time was 107 ± 19.0 minutes and cross-clamp time was 49 ± 7.9 minutes. This technology readily provides multiple pass recirculation of genes through the heart with minimal side effects of collateral expression of other organs.

Entities:  

Keywords:  cardiopulmonary bypass; gene therapy; heart isolation; heart perfusion

Mesh:

Year:  2018        PMID: 30250349      PMCID: PMC6146280     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  14 in total

1.  Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation.

Authors:  Charles R Bridges; James M Burkman; Ramin Malekan; Stephane M Konig; Haiyan Chen; Charles B Yarnall; Timothy J Gardner; Alan S Stewart; Mark M Stecker; Terry Patterson; Hansell H Stedman
Journal:  Ann Thorac Surg       Date:  2002-06       Impact factor: 4.330

2.  Retrograde coronary perfusion: a superior route to deliver therapeutics to the heart?*.

Authors:  Frank J Giordano
Journal:  J Am Coll Cardiol       Date:  2003-09-17       Impact factor: 24.094

3.  Cardiac gene delivery with cardiopulmonary bypass.

Authors:  M J Davidson; J M Jones; S M Emani; K H Wilson; J Jaggers; W J Koch; C A Milano
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

Review 4.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

5.  Potential of gene therapy as a treatment for heart failure.

Authors:  Roger J Hajjar
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

Review 6.  Current concepts and applications of coronary venous retroinfusion.

Authors:  Peter Boekstegers; Christian Kupatt
Journal:  Basic Res Cardiol       Date:  2004-11       Impact factor: 17.165

7.  Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2+) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathy.

Authors:  Michael G Katz; Anthony S Fargnoli; Richard D Williams; Nury M Steuerwald; Alice Isidro; Anna V Ivanina; Inna M Sokolova; Charles R Bridges
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-07       Impact factor: 5.209

Review 8.  Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives.

Authors:  Michael G Katz; Anthony S Fargnoli; Andrew P Kendle; Roger J Hajjar; Charles R Bridges
Journal:  Ann Thorac Surg       Date:  2016-01-20       Impact factor: 4.330

9.  Mitigation of myocardial fibrosis by molecular cardiac surgery-mediated gene overexpression.

Authors:  Michael G Katz; Elizabeth Brandon-Warner; Anthony S Fargnoli; Richard D Williams; Andrew P Kendle; Roger J Hajjar; Laura W Schrum; Charles R Bridges
Journal:  J Thorac Cardiovasc Surg       Date:  2015-11-25       Impact factor: 5.209

10.  Adenoviral gene transfer to the heart during cardiopulmonary bypass: effect of myocardial protection technique on transgene expression.

Authors:  J M Jones; K H Wilson; W J Koch; C A Milano
Journal:  Eur J Cardiothorac Surg       Date:  2002-05       Impact factor: 4.191

View more
  1 in total

1.  Kappa opioid receptor agonists improve postoperative cognitive dysfunction in rats via the JAK2/STAT3 signaling pathway.

Authors:  Xi Li; Yingjie Sun; Qiang Jin; Dandan Song; Yugang Diao
Journal:  Int J Mol Med       Date:  2019-09-13       Impact factor: 4.101

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.